Neuland Labs Exports Surge 143% MoM to $20.4M

Neuland Laboratories reported a significant 143% month-on-month increase in exports, reaching $20.4 million, demonstrating strong international business growth and operational momentum.

Neuland Laboratories Approves 1.89 Billion Rupees Investment for New R&D Center

Neuland Laboratories has approved an investment of 1.89 billion rupees for establishing a new research and development center. This significant capital allocation demonstrates the pharmaceutical company's commitment to expanding its R&D capabilities and strengthening its innovation infrastructure.

Neuland Laboratories Approves ₹1.89 Billion Investment for New R&D Center

Neuland Laboratories has approved an investment of ₹1.89 billion for establishing a new research and development center. This significant capital allocation demonstrates the company's commitment to expanding its R&D capabilities and strengthening its pharmaceutical development infrastructure.

Neuland Laboratories Reports Record Revenue of Rs 516 Crore in Q2, Up 63.7% Year-on-Year

Neuland Laboratories achieved its highest quarterly revenue of Rs 516 crore in Q2, representing a 63.7% increase from Rs 315 crore in the same period last year. The growth was primarily driven by commercial CMS (Contract Manufacturing Services) projects, with the company's top two commercial CMS molecules performing well. EBITDA stood at Rs 156.9 crore with a margin of 30.4%, while profit after tax reached Rs 96.5 crore compared to Rs 32 crore in Q2 of the previous year. EPS for the quarter was Rs 75.18 per share. The company expects commercialization of another molecule this year and reported strong customer interest in its peptide capabilities. Working capital increased to 155 days of sales due to higher inventories and receivables. CAPEX for the quarter was Rs 91 crore, with Rs 170.7 crore invested in the six-month period. The company's peptide facility investment is progressing as planned, with Module-1 expected to be operational in the next financial year.